Randomized trials have shown that liraglutide and semaglutide can improve walking distance in people with PAD, while observational studies have linked semaglutide and tirzepatide to lower risks of amputation, lower-extremity revascularization, and mortality
Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others approximately 14 of the original 19 restricted compounds
Short-Term GLP-1 Side Effects You May Experience Long-Term GLP-1 Side Effects And Risks Dumping Syndrome And GLP-1: Is There A Connection
W modelach to przekada si na silniejszy efekt metaboliczny ni agonizm samego GLP-1 (Mller i wsp